IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 675 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
 » Next article
 » Previous article 
 » Table of Contents
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (337 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  Abstract
 »  Introduction
 »  Materials and Me...
 »  Results
 »  Discussion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed4195    
    Printed134    
    Emailed9    
    PDF Downloaded450    
    Comments [Add]    
    Cited by others 6    

Recommend this journal

 


 
RESEARCH ARTICLE
Year : 2010  |  Volume : 42  |  Issue : 1  |  Page : 40-43
 

Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study


1 Department of Pharmacology, JIPMER, Pondicherry, India
2 MBBS Student, JIPMER, Pondicherry, India
3 Department of Radiotherapy, JIPMER, Pondicherry, India

Date of Submission30-Jul-2009
Date of Decision12-Oct-2009
Date of Acceptance12-Mar-2010
Date of Web Publication12-Apr-2010

Correspondence Address:
A Surendiran
Department of Pharmacology, JIPMER, Pondicherry
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.62412

Rights and Permissions

 » Abstract 

Aims : This prospective study was designed to monitor and analyze the pattern of occurrence of adverse drug reactions (ADRs) to cisplatin-based chemotherapy regimen in the cancer ward of a tertiary care hospital.
Materials and Methods : Cancer patients who received cisplatin-based cancer chemotherapy were monitored for adverse reactions. The collected reports were analyzed for demographic and drug details, causality, preventability and severity of adverse effects. Causality was assessed by the World Health Organization (WHO) causality assessment scale and Naranjo's Algorithm. Preventability and severity of ADRs were assessed by modified Schumock and Thornton scale, modified Hartwig and Siegel scale respectively.
Results : Among 51 patients, 48 developed ADRs to cisplatin chemotherapy. The reactions observed were nausea, alopecia, anorexia, vomiting, taste alteration, diarrhea, constipation, tinnitus, and hypocalcaemia. The WHO causality assessment scale indicated 69% "possible" and 31% "probable" but no "certain" reactions. Naranjo's Algorithm showed 62% "probable" and 38% "possible" reactions. Most of the reactions belonged to the category of "not preventable". Reactions like nausea and vomiting belonged to the category of "definitely preventable". Modified Hartwig and Siegel scale of severity assessment showed that most of the reactions were of "mild level 1" severity except for vomiting, diarrhea and hypocalcaemia, which were of "moderate level 3" severity.
Conclusion : Cisplatin-based chemotherapy has a high potential to cause adverse effects. Most of the reactions were of milder nature but not preventable. The common adverse effects such as nausea and vomiting were preventable, but reactions like hypersensitivity reactions and anaphylaxis were not predictable.


Keywords: Chemotherapy, cisplatin, pharmacovigilance


How to cite this article:
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K S, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol 2010;42:40-3

How to cite this URL:
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K S, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol [serial online] 2010 [cited 2019 Feb 21];42:40-3. Available from: http://www.ijp-online.com/text.asp?2010/42/1/40/62412



 » Introduction Top


Pharmacovigilance deals with detection, assessment and prevention of adverse drug reactions (ADRs). [1] Drug toxicity is a major limitation in providing healthcare to patients at a global level. It affects the patient's recovery as well the economy of healthcare. With the increase in production of various pharmaceutical products, newer drugs are being introduced every year. Hence, the need for an active surveillance system to remove the harmful drugs that have entered the market was well realized by the World Health Organization (WHO). This has been the basis for starting the International Drug Monitoring Program by the WHO.

The National Pharmacovigilance Program in India was started with the objectives of monitoring the safety of drugs and creation of an adverse drug reaction database for the Indian population. [1] The major aims of pharmacovigilance are early detection of unknown adverse reactions, detection of increase in frequency of known adverse reactions, identification of risk factors and dissemination of information. [2]

Cancer chemotherapeutic drugs like cisplatin have a very high potential for drug toxicity. [3] However, the number of ADR reports from the cancer wards to the pharmacovigilance center of our hospital was minimal. The reason for this paradox was not clear. It could be either due to gross underreporting of adverse drug reactions or due to effective preventive measures being adopted for the patients receiving cancer chemotherapy. As cisplatin is one of the most commonly used drugs for cancer chemotherapy, we did a focused monitoring of adverse drug reaction profile of cisplatin-based chemotherapeutic regimen. This study was designed to prospectively monitor and analyze the pattern of occurrence of ADRs to cisplatin-based chemotherapy regimen in the cancer ward of our tertiary care hospital.


 » Materials and Methods Top


This prospective study was carried out by the Pharmacovigilance Center of a tertiary care hospital, among inpatients of oncology ward in the Regional Cancer Center of the hospital, over a period of two months. The Institutional Ethics Committee approval was obtained prior to initiation of study. The pharmacovigilance system consisted of notification forms, drop boxes [4] and a coordinated Drug Information Center. The cancer wards were fitted with drop boxes with a label for pharmacovigilance system along with notification forms by their side. The physicians had been instructed to fill the notification forms about the adverse drug reaction and put them in the drop boxes, which were then collected by the Pharmacovigilance Center. The ADR were assessed for causality, severity and preventability.

Cancer patients belonging to either gender and of all ages, who were receiving cisplatin-based cancer chemotherapy under any standard regimen, were included for the study. Those patients who did not receive cisplatin as part of the drug regimen were excluded from the study. The patients received cancer chemotherapy as per the assessment of the treating physician. No changes in the treatment decision, schedule or duration were made as a part of the study. The patients admitted for cancer chemotherapy and receiving cisplatin as part of the regimen were monitored for adverse effects till their discharge from hospital.

All the patients received pre-medication with intravenous ranitidine, dexamethasone and ondansetron to avoid emesis, as cisplatin is a highly emetogenic drug. [5] They were also administered post-medication with intravenous mannitol to avoid nephrotoxicity. Monitoring for adverse effects was done based on daily questioning for symptoms. The collected reports were documented in the case report form and analyzed for demographic details, drug details, causality, preventability and severity of adverse effects. Causality was assessed by both WHO causality assessment scale [6] and Naranjo's Algorithm. [7] Preventability was assessed by modified Schumock and Thornton scale. [8] The severity of ADRs was assessed by modified Hartwig and Siegel scale. [9]

The WHO causality assessment scale is recommended by the WHO Uppsala Monitoring Center, which is the WHO collaborating Center for International Drug Monitoring, [6] for evaluation of the causal relationship of drugs to its adverse effects. The Naranjo's Algorithm, a questionnaire designed by Naranjo et al. consists of objective questions with three types of responses - yes, no or do not know. Scores are given accordingly and the drug reaction can be classified as definite, probable or possible. The modified Schumock and Thornton scale classifies ADRs as definitely preventable, probably preventable and not preventable based on a set of questions for each level. The modified Hartwig and Siegel scale classifies severity of ADR as mild, moderate or severe with various levels according to factors like requirement for change in treatment, duration of hospital stay, and the disability produced by the adverse drug reaction.

No invasive investigation was undertaken or suggested to the treating physician by the investigator as a part of the study. The drug effects which were described by the patients and effects which were diagnosed and reported by the physician were documented.


 » Results Top


The adverse drug reaction reports were obtained by regular questioning of patients by the investigator in the evening hours of working days. Out of 48 patients with adverse drug reactions, only one case was spontaneously reported to the Regional Pharmacovigilance Center by the health care worker in the ward. At the end of the study period, a total of 51 patients who received cisplatin-based chemotherapy were monitored for adverse reactions till their discharge from hospital. This included 17 male patients and 34 female patients. The various indications for its use were carcinoma of cervix, lung with metastasis, oral cavity, ovary and thymomas. The most common indication was cervical carcinoma. Among the 51 patients observed, 48 developed adverse reactions to the chemotherapy regimen. This included 25 patients receiving cisplatin alone, 22 patients receiving cisplatin along with one additional anti cancer agent (5-fluorouracil, paclitaxel, ifosfamide, gemcitabine) and one patient receiving cisplatin with two additional anticancer agents (adriamycin and ifosfamide). Twenty patients who developed ADRs received concomitant radiotherapy. Only three out of 51 patients did not develop ADRs to cisplatin chemotherapy.

The ADRs observed in the patients were nausea, alopecia, anorexia, vomiting, taste alteration, diarrhea, constipation, tinnitus, and hypocalcaemia [Figure 1]. Assessment of causality by WHO causality assessment scale [6] indicated that 69% of the reactions belong to the category "possible", followed by the category "probable" with frequency of 31% [Table 1]. There were no "certain" reactions as re challenge was not attempted in any of the patients. However, the grade of causality for each ADR remained low due to presence of co-administered drugs. As per Naranjo's Algorithm [7] almost 62% of the ADRs were categorized as "probable" with score ranging from 5 - 8 and 38% of the ADRs were categorized as "possible" with score ranging from 1 - 4 [Table 2]. Assessment of preventability of the ADR was done based on modified Schumock and Thornton scale [8] [Table 3]. Most of the ADRs belonged to the category of "not preventable". However, the more common reactions like nausea and vomiting belonged to the category of "definitely preventable". Based on modified Hartwig and Siegel scale [9] of severity assessment, most of the reactions were of less severity categorized as "mild level 1" severity, except for vomiting, diarrhea and hypocalcaemia, which were categorized as "moderate level 3" severity.


 » Discussion Top


Cisplatin is a commonly used anti neoplastic agent. Some of the well documented ADRs of this drug include nausea, vomiting [5],[10] renal toxicity, [11],[12],[13] ototoxicity, [14] peripheral neuropathy, [15] hypersensitivity reactions [16] and electrolyte disturbances. [17],[18],[19],[20],[21],[22] Most of the ADRs documented in this study comprised one or more of these reactions. Although adequate pre-medication with parenteral dexamethasone, ranitidine and ondansetron were given to each patient, the frequency of nausea and vomiting remained high due to the high emetogenic potential of cisplatin. The most frequent adverse effects include nausea, alopecia, anorexia and vomiting [Figure 1]. The study has demonstrated the need to improve the management of nausea and vomiting, since the rates of prevention of these expected adverse effects of cisplatin were poor. Some of the rarer reactions include hypocalcaemia, headache, salivation and dizziness. Pretreatment values of complete hemogram were taken for every patient before each cycle and post treatment assessment was done only if clinically indicated. There were no reports of hematological disturbances.

Nausea and vomiting are very common side effects of cancer chemotherapeutic drugs. [10] These drugs may induce vomiting by both a central action on the chemoreceptor trigger zone (CTZ) and a peripheral action on the gastrointestinal tract. The dominant receptors in the CTZ located in the floor of the fourth ventricle are serotonin Type 3 (5-HT3) and dopamine Type 2 (D2). [23] As serotonin receptors in the brain are involved in the mechanism of acute onset vomiting, ondansetron has a definite role in its prevention. [24] Ototoxicity can be more severe in children. It can manifest as tinnitus and loss of hearing in the high frequency range. [14] Electrolyte disturbances such as hypomagnesaemia, hyponatremia, hypocalcaemia and hypokalemia are known to occur. [17],[18],[19],[20],[21],[22] We observed that 51% of patients studied developed alopecia. Earlier studies have shown conflicting results implicating cisplatin as a common causative agent for alopecia as well as an unlikely agent for alopecia. [25],[26],[27] In our study, out of 26 patients who developed alopecia, 14 were on monotherapy with cisplatin, seven had concurrent ifosfamide, two had concurrent 5-fluorouracil, and one each had paclitaxel, adriamycin plus ifosfamide and gemcitabine. Among patients who developed alopecia, more than 50% were on monotherapy with cisplatin. Diarrhea can occur due to mucosal cell toxicity. Animal studies have demonstrated the effect of cisplatin causing specific mitochondrial oxidative DNA damage in gastro intestinal mucosal cells and increased gastro intestinal permeability, an indicator of toxicity. [28]

A study by Bahl et al, [26] on 40 patients with locally advanced non small cell lung cancer, treated with cisplatin and etoposide, described the ADR pattern to cisplatin. However, our study included all patients who were under therapy with cisplatin-based chemotherapy regimen irrespective of their diagnosis. The frequency of alopecia was reported as 88% in their study compared to 51% in our study. Occurrence of nausea and vomiting had similar frequency in both studies. Anorexia had a slightly higher frequency in them (52%) compared to our study (43%). Though these studies reported hematological abnormalities like leucopenia, anemia and thrombocytopenia, we did not observe such effects.

In the present study, almost all the ADRs except anorexia and hypocalcaemia assessed as "possible" with lower level of causality by WHO scale had been identified as "probable" with higher level of causality based on Naranjo's Algorithm. This shows the more objective nature of Naranjo's Algorithm. There were no "certain" drug reactions as the patients were not subjected to re challenge of the drug. There were no "unlikely" drug reactions as the investigator was trained in methods of pharmacovigilance and such complaints were avoided.

Most of the ADRs were not preventable due to the poor predictability of the ADRs and poorly understood mechanisms to explain their cause. However, with adequate pre-medication, common ADRs like nausea and vomiting can be effectively controlled. This brings out the possible toxicity that the treating physician should anticipate and counsel the patient adequately prior to starting of therapy.

Most of the reactions were of less severity and there would be no strong indication to change or withhold the drug for milder adverse effects. Similar studies can be used as audit tools for iatrogenic adverse events and assessment of prevention of expected adverse drug reactions.

There is a need for effective pharmacovigilance in India owing to absence of Indian data on adverse effects and the genetic diversity of the Indian population. [29] This study had carried out a focused ADR monitoring on cisplatin-based chemotherapy for cancer patients, though there were anecdotal case reports of adverse reactions to cisplatin.

In conclusion, cisplatin-based chemotherapy has a high potential to cause various adverse effects in cancer patients. Most of the adverse drug reactions in this study were mild, but not preventable; hence they do not affect the treatment. It should also be noted that though the common adverse effects such as nausea and vomiting were preventable, most of the idiosyncratic reactions like hypersensitivity reactions and anaphylaxis were non-specific and not predictable. This study also emphasizes the need to improve pharmacovigilance awareness among physicians in order to improve the pharmacovigilance system in India.

 
 » References Top

1.Adithan C. National pharmacovigilance programme. Indian J Pharmacol 2005;37:347.  Back to cited text no. 1    Medknow Journal  
2.World Health Organization. Safety monitoring of medicinal products. Guidelines for setting up and running a pharmacovigilance centre. Available from: http://www.who-umc.org/graphics/4807.pdf">http://www.who-umc.org/graphics/4807.pdf [last cited on 2008 Dec 31].  Back to cited text no. 2      
3.Aggarwal SK. Calcium modulation of toxicities due to Cisplatin. Met Based Drugs 1998;5:77-81.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Drop box. Uppsala Reports. Available from http://www.who-umc.org/graphics/9628.pdf. [last cited on 2008 Dec 31].   Back to cited text no. 4      
5.O′Brien C. Nausea and vomiting. Can Fam Physician 2008;54:861-3.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]  
6.World Health Organization. Uppsala Monitoring Center. Causality Assessment of Suspected Adverse Reactions. Available from: http://www.who-umc.org/DynPage.aspx?id=22682. [last cited on 2008 Dec 31].   Back to cited text no. 6      
7.Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  Back to cited text no. 7  [PUBMED]    
8.Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538.  Back to cited text no. 8  [PUBMED]    
9.Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.  Back to cited text no. 9  [PUBMED]    
10.Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 2007;12:1143-50.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]  
11.Joy J, Nair CK. Amelioration of cisplatin induced nephrotoxicity in Swiss albino mice by Rubia cordifolia extract. J Cancer Res Ther 2008;4:111-5.  Back to cited text no. 11  [PUBMED]  [FULLTEXT]  
12.Fillastre JP, Raguenez-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett 1989;46:163-75.  Back to cited text no. 12  [PUBMED]  [FULLTEXT]  
13.Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal toxicity: Possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 1997;8:1640-4.  Back to cited text no. 13  [PUBMED]  [FULLTEXT]  
14.Kaltenbach JA, Rachel JD, Mathog TA, Zhang J, Falzarano PR, Lewandowski M. Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: Relevance to tinnitus. J Neurophysiol 2002;88:699-714.  Back to cited text no. 14  [PUBMED]  [FULLTEXT]  
15.Macdonald DR. Neurologic complications of chemotherapy. Neurol Clin 1991;9:955-67.  Back to cited text no. 15  [PUBMED]    
16.Touraine F, Sainte Laudy J, Boumediene A, Ndikumwenayo F, Decroisette C, Melloni B, et al. Investigation of allergic reactions to platinum salts. Rev Mal Respir 2006;23:458-62.  Back to cited text no. 16      
17.Atsmon J, Dolev E. Drug-induced hypomagnesaemia: Scope and management. Drug Saf 2005;28:763-88.  Back to cited text no. 17  [PUBMED]  [FULLTEXT]  
18.Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N. Cisplatin-induced hypokalemic paralysis. Clin Ther 2004;26:1320-3.  Back to cited text no. 18  [PUBMED]  [FULLTEXT]  
19.Rodriguez M, Solanki DL, Whang R. Refractory potassium repletion due to cisplatin-induced magnesium depletion. Arch Intern Med 1989;149:2592-4.  Back to cited text no. 19  [PUBMED]  [FULLTEXT]  
20.Shibata H. Treatment for the electrolytic disorders in cancer patients. Gan To Kagaku Ryoho 2008;35:2330-3.  Back to cited text no. 20  [PUBMED]  [FULLTEXT]  
21.Maina A, Richiardi G, Danese S, Defabiani E, Giardina G. Symptomatic hypocalcemia and hypomagnesiemia in cisplatinum-based chemotherapy treated patients: Case report. Eur J Gynaecol Oncol 1996;17:281-2.  Back to cited text no. 21  [PUBMED]    
22.Brousse C, Baumelou E, Mignot L. Hypocalcemia caused by hypomagnesemia during a treatment with cisplatin. Rev Med Interne 1996;17:498.  Back to cited text no. 22  [PUBMED]  [FULLTEXT]  
23.Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004;69:1169-74.  Back to cited text no. 23  [PUBMED]  [FULLTEXT]  
24.Warr DG. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol 2008;15:S4-9.  Back to cited text no. 24  [PUBMED]  [FULLTEXT]  
25.Chadha V, Shenoi SD. Hair loss in cancer chemotherapeutic patients. Indian J Dermatol Venereol Leprol 2003;69:131-2.  Back to cited text no. 25  [PUBMED]  Medknow Journal  
26.Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. J Cancer Res Ther 2006;2:14-6.  Back to cited text no. 26  [PUBMED]  [FULLTEXT]  
27.Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003;8:72-5.  Back to cited text no. 27  [PUBMED]    
28.Yanez JA, Teng XW, Roupe KA, Fariss MW, Davies NM. Chemotherapy induced gastrointestinal toxicity in rats: Involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2. J Pharm Pharm Sci 2003;6:308-14.  Back to cited text no. 28      
29.Papiha SS. Genetic variation in India. Hum Biol 1996;68:607-28.  Back to cited text no. 29      


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity
Siddik Ugur,Ramazan Ulu,Ayhan Dogukan,Ali Gurel,Irem Pembegul Yigit,Nevzat Gozel,Bilge Aygen,Necip Ilhan
Renal Failure. 2015; : 1
[Pubmed] | [DOI]
2 The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma
Hai-feng Wang,Jie-qing Lv
Cell Biochemistry and Biophysics. 2015;
[Pubmed] | [DOI]
3 Comparative In Vivo Evaluations of Curcumin and Its Analog Difluorinated Curcumin Against Cisplatin-Induced Nephrotoxicity
Kazim Sahin,Cemal Orhan,Mehmet Tuzcu,Irfana Muqbil,Nurhan Sahin,Hasan Gencoglu,Osman Guler,Subhash B. Padhye,Fazlul H. Sarkar,Ramzi M. Mohammad
Biological Trace Element Research. 2014;
[Pubmed] | [DOI]
4 A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital
M. Shamna,C. Dilip,M. Ajmal,P. Linu Mohan,C. Shinu,C.P. Jafer,Yahiya Mohammed
Saudi Pharmaceutical Journal. 2013;
[Pubmed] | [DOI]
5 Science behind cisplatin-induced nephrotoxicity in humans: A clinical study
Arunkumar, P.A., Viswanatha, G.L., Radheshyam, N., Mukund, H., Belliyappa, M.S.
Asian Pacific Journal of Tropical Biomedicine. 2012; 2(8): 640-644
[Pubmed]
6 Science behind cisplatin-induced nephrotoxicity in humans: A clinical study
PA Arunkumar,GL Viswanatha,N Radheshyam,H Mukund,MS Belliyappa
Asian Pacific Journal of Tropical Biomedicine. 2012; 2(8): 640
[Pubmed] | [DOI]



 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow